head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2021, vol. 27, issue1
Subject Area: Medicine
DOI: 10.5272/jimab.2021271.3652
Published online: 29 March 2021

Review article

J of IMAB. 2021 Jan-Mar;27(1):3652-3657
Svetoslav Tsenov1ORCID logo, Evgeni Grigorov1, 2ORCID logo Corresponding Autoremail, Valentina Belcheva2ORCID logo,
1) National Center of Public Health and Analyses, Sofia, Bulgaria.
2) Department Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Varna, Bulgaria.

Cardiovascular (CV) diseases are a major burden for all the healthcare systems around the world. Public health and medical advances continue to beneficially affect CV patients health. In the last decades, many new medicinal products for hearth problems were discovered and received a marketing authorization.
Elevated low-density lipoprotein cholesterol (LDL-C) levels have been linked to major CV risk. The objective of this study was to review the medical needs in high-risk cardiovascular patients with familial hypercholesterolemia undergoing pharmacological treatment with statins and the degree of attained lipid control.
A conclusion it can be stated, that there is a significant unmet medical need for a potentially effective treatment, which can supplement the statin therapy, enabling vulnerable populations to achieve sufficient control of LDL-C, and thus provide an alternative for patients with statin intolerance or where this group of medicinal products are not clinically appropriate.

Keywords: unmet, medical, needs, high-risk, cardiovascular, patients, familial, hypercholesterolemia,

pdf - Download FULL TEXT /PDF 1229 KB/
Please cite this article as: Tsenov S, Grigorov E, Belcheva V. Unmet Medical Needs in High-risk Cardiovascular Patients with Familial Hypercholesterolemia. J of IMAB. 2021 Jan-Mar;27(1):3652-3657. DOI: 10.5272/jimab.2021271.3652

Corresponding AutorCorrespondence to: Assoc. prof. Evgeni Grigorov, PhD, MScPharm, MHM, Department Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Varna; 84, Tzar Osvoboditel blvd., Varna 9000, Bulgaria; E-mail: evgeni.grigorov@mu-varna.bg

1. National Center of Public Health and Analysis. [Morbidity of Population. Public Health Statistics Annual Bulgaria.] [in Bulgarian] 2018. [Internet]
2. National Statistical Institute. Demographic and social statistics. 2015. [Internet]
3. Dyakova M, Shipkovenska E, Dyakov P, Dimitrov P, Torbova S. Cardiovascular risk assessment of Bulgarian urban population: cross-sectional study. Croat Med J. 2008 Dec;49(6):783–91. [PubMed] [Crossref]
4. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459–72. [PubMed] [Crossref]
5. Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won’t Do! Drugs. 2016 Aug 25;76(12):1175–90. [PubMed] [Crossref]
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 282(24):2340–6. [PubMed] [Crossref]
7. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005 Oct 4;46(7):1225–8. [PubMed] [Crossref]
8. Mora S, Wenger NK, DeMicco DA, Breazna A, Boekholdt SM, Arsenault BJ, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. [PubMed] [Crossref]
9. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004 Jul 13;110(2):227–39. [Crossref]
10. Martin SS, Blumenthal RS, Miller M. LDL Cholesterol: The Lower the Better. Med Clin North Am. 2012 Jan;96(1):13–26. [Crossref]
11. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009 Jul 7;120(1):28–34. [PubMed] [Crossref]
12. Sampson UK, Fazio S, Linton MF. Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Curr Atheroscler Rep. 2012 Feb;14(1):1–10. [PubMed] [Crossref]
13. Georgiev KD, Hvarchanova N, Georgieva M, Kanazirev B. The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients. Int J Clin Pharm. 2019 Dec 8;41(6):1555–61. [PubMed] [Crossref]
14. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. [PubMed] [Crossref]
15. Wanner C, Krane V, März, W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238-48. [PubMed] [Crossref]
16. Grigorov E, Lebanova H, Naseva E, Getov I. [Pilot study for total cholesterol measurement among patients with IHD at community pharmacies in Sofia.] [in Bulgarian] MR - Cardiovasc Dis. 2012;43(3):36-40. [Internet]
17. Georgiev K, Hvarchanova N, Georgieva M, Kanazirev B. Potential drug-drug interactions in heart failure patients. Int J Pharm Pharm Sci. 2019 Jul 25;11(9):37–41. [Crossref]
18. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun 26;326(7404):1423. [PubMed] [Crossref]
19. Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol. 2000 Jun;40(6):616–23. [PubMed] [Crossref]
20. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15;92(2):152–60. [PubMed] [Crossref]
21. Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs. 2010 Jul 30;70(11):1363–79. [PubMed] [Crossref]
22. Paramsothy P. Management of dyslipidaemias. Heart. 2006 Oct;92(10):1529–34. [PubMed] [Crossref]
23. Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012 Jul-Aug;6(4):303-9. [PubMed] [Crossref]
24. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J. 2013 Sep;166(3):597–603. [PubMed] [Crossref]
25. McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract. 2016 Nov;70(11):886-97. [PubMed] [Crossref]
26. Jennings C, Graham I, Gielen S. The ESC The ESC Handbook of Preventive Cardiology: Putting Prevention Into Practice. Edited by Jennings C, Graham I, Gielen S. Oxford University Press. 2016. p.352. [Internet]
27. Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016 Apr;23(6):636-48. [PubMed] [Crossref]
28. Lebanova H, Getov I. Patient Reporting Of Adverse Drug Events – A Narrative Review. Scr Sci Pharm. 2014 Jun;1(1):14. [Crossref]
29. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008 May 20;29(21):2625-33. [PubMed] [Crossref]
30. Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec;135(2):249–56. [PubMed] [Crossref]
31. Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High Dose Statin Therapy. J Am Heart Assoc. 2013 Apr 24;2(2):e000028. [PubMed] [Crossref]
32. Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol. 2014 Jan-Feb;8(1):18-28. [PubMed] [Crossref]
33. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431–43. [PubMed] [Crossref]
34. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep. 2002 Jan;4(1):19–25. [PubMed] [Crossref]
35. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002 Jul;163(1):157–64. [PubMed] [Crossref]
36. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003 Dec 1;92(11):1287–93. [PubMed] [Crossref]
37. Beliard S, Carreau V, Carrie A, Giral P, Duchene E, Farnier M, et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis. 2014 May;234(1):136-41. [PubMed] [Crossref]
38. Hermans MP, Castro Cabezas M, Strandberg T, Ferriиres J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 Feb 14;26(2):445-54. [PubMed] [Crossref]
39. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul 2;32(14):1769-818. [PubMed] [Crossref]
40. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010 Mar;209(1):189-94. [PubMed] [Crossref]
41. Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, et al. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. J Clin Lipidol. 2018 Jul-Aug;12(4):972-980.e1. [PubMed] [Crossref]
42. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012-22. [PubMed] [Crossref]
43. Sniderman A. Targets for LDL-lowering therapy. Curr Opin Lipidol. 2009 Aug;20(4):282–7. [PubMed] [Crossref]
44. Orso E, Ahrens N, Kilalic D, Schmitz G. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors. Atheroscler Suppl. 2009 Dec;10(5):74–8. [PubMed] [Crossref]
45. Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia. Am J Cardiol. 2008 Dec;102(11):1438–43. [PubMed] [Crossref]
46. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar;197(1):400–6. [PubMed] [Crossref]
47. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148–56. [PubMed] [Crossref].

Received: 27 April 2020
Published online: 29 March 2021

back to Online Journal